{rfName}
Du

Indexed in

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Castañeda SAuthorGarcía-Vicuña RAuthor

Share

November 13, 2023
Publications
>
Article

Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

Publicated to:Frontiers in Immunology. 14 1283251- - 2023-10-23 14(), DOI: 10.3389/fimmu.2023.1283251

Authors: Valero-Martínez, C; Castañeda, S; García-Vicuña, R; Urgelles, JF; Sallés, M; Joven-Ibáñez, BE; de Juanes, A; Ramírez, J; Juanola, X; Almodóvar, R; Laiz, A; Moreno, M; Pujol, M; Beltrán, E; Pinto-Tasende, JA; Crespí, L; Sala-Icardo, L

Affiliations

Althaia Xarxa Assistencial de Manresa - Author
Althaia Xarxa Assistencial Univ, Rheumatol Unit, Manresa, Spain - Author
Complexo Hosp Univ A Coruna, Rheumatol Unit, La Coruna, Spain - Author
Hosp Badalona Germans Trias & Pujol, Rheumatol Unit, Badalona, Spain - Author
Hosp Clin Barcelona, Rheumatol Unit, Barcelona, Spain - Author
Hosp del Mar, Rheumatol Unit, Barcelona, Spain - Author
Hosp Manacor, Rheumatol Unit, Manacor, Spain - Author
Hosp Santa Creu & Sant Pau, Rheumatol Unit, Barcelona, Spain - Author
Hosp Torrejon de Ardoz, Rheumatol Unit, Madrid, Spain - Author
Hosp Univ Bellvitge, Rheumatol Unit, Barcelona, Spain - Author
Hosp Univ Fdn Alcorcon, Rheumatol Unit, Madrid, Spain - Author
Hosp Univ La Princesa, Rheumatol Unit, IIS Princesa, Madrid, Spain - Author
Hosp Univ Mutua Terrassa, Rheumatol Unit, Barcelona, Spain - Author
Hosp Univ Octubre 12, Rheumatol Dept, Madrid, Spain - Author
Hospital Clinic Barcelona - Author
Hospital de la Santa Creu i Sant Pau - Author
Hospital de Manacor - Author
Hospital de Torrejón de Ardoz - Author
Hospital del Mar - Author
Hospital Universitari de Bellvitge - Author
Hospital Universitari Germans Trias i Pujol - Author
Hospital Universitario 12 de octubre - Author
Hospital Universitario de la Princesa - Author
Hospital Universitario Fundación Alcorcón - Author
Parc Taulí University Hospital - Author
Rheumatology Unit - Author
UAB, Hosp Univ Parc Tauli, I3PT, Rheumatol Unit, Sabadell, Spain - Author
Univ Autonoma Madrid UAM, Catedra Univ Autonoma Madrid UAM Roche, Dept Med, Enfermedad Pulm Intersticial Difusa EPID Future, Madrid, Spain - Author
Univ Autonoma Madrid UAM, Dept Med, Madrid, Spain - Author
Univ. A. - Author
Universidad Autónoma de Madrid , Hospital Universitario de la Princesa - Author
See more

Abstract

Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. This is a retrospective, real-world multicenter study in refractory SpA and PsA patients with simultaneous use of two biological or synthetic targeted agents. Effectiveness was assessed using Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Disease Activity in Psoriatic Arthritis (DAPSA) Score. We identified 39 different DTT combinations in 36 patients (22 SpA; 14 PsA), 25 of them with concomitant inflammatory bowel disease. The most commonly used combinations were TNF inhibitor plus antagonist of the IL12/23 pathway, followed by TNF inhibitor plus IL-17 antagonist. During a median exposure of 14.86 months (IQR 8-20.2), DTT retention rate was 69.4% (n=25/36; 19 SpA, 6 PsA). Major clinical improvement (change in ASDAS-CRP > 2 or improvement > 85% in DAPSA) was achieved in 69.4% of patients (n=25/36 therapeutical combinations; 17/21 SpA, 8/15 PsA), with a 58.3% (n=21/36 combinations; 15/20 SpA, 6/13 PsA) low-activity/remission rate. Of the patients who were receiving glucocorticoids, 55% managed to withdraw them during follow-up. Interestingly, only four serious adverse events in three patients were observed, leading to DTT discontinuation.

Keywords

anti-tnfcase-seriesclassification criteriacombination (combined) therapycombination therapyinflammatory bowel diseasemulticenter studynecrosis-factor-alphapsoriatic arthritis (psa)real word datarefractory psoriasisrheumatoid-arthritissafetyspondyloarthritisvedolizumabBiologicsCombination (combined) therapyInflammatory bowel diseaseInflammatory-bowel-diseaseMulticenter studyPsoriatic arthritis (psa)Real word dataSafetySpondyloarthritis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Frontiers in Immunology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 37/181, thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 13.54, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 5
  • Scopus: 5

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 22.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 30 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 17.3.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 16 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (GARCIA DE VICUÑA PINEDO, MARIA DEL ROSARIO).